Pharmaceutical

Bayer subsidiary Vividion secures rights to Werner helicase inhibitor

Vividion Therapeutics has secured worldwide rights for developing and commercialising VVD-214, the Werner helicase (WRN) covalent inhibitor.

Jun 7, 2025 - 06:00
Bayer subsidiary Vividion secures rights to Werner helicase inhibitor
Vividion Therapeutics has secured worldwide rights for developing and commercialising VVD-214, the Werner helicase (WRN) covalent inhibitor.
Read the original article

Tags:

Previous Article

‘Dupixent-fuelled’ atopic dermatitis market sales to hit $22.4bn by 2033

Next Article

MHRA warns women using weight loss jabs must use effective contraception

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

GSK’s Jemperli approved for advanced endometrial cancer in Singapore

GSK’s Jemperli approved for advanced endometrial cancer...

Aug 9, 2024

PRO-1107 by ProfoundBio Suzhou for Fallopian Tube Cance...

Apr 21, 2024

Granite Bio secures $100m in funding for new antibodies

Granite Bio secures $100m in funding for new antibodies

Apr 26, 2025